335 related articles for article (PubMed ID: 23519309)
1. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
2. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
[TBL] [Abstract][Full Text] [Related]
3. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
[TBL] [Abstract][Full Text] [Related]
4. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S50-5. PubMed ID: 23519305
[TBL] [Abstract][Full Text] [Related]
5. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
[TBL] [Abstract][Full Text] [Related]
6. Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S64-8. PubMed ID: 23519307
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
[TBL] [Abstract][Full Text] [Related]
8. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
[TBL] [Abstract][Full Text] [Related]
9. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
[TBL] [Abstract][Full Text] [Related]
10. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
11. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LA; Myers O; Cuzick J; Wentzensen N; Kinney W; Castle PE; Wheeler CM;
Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
[TBL] [Abstract][Full Text] [Related]
12. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
[TBL] [Abstract][Full Text] [Related]
13. Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.
Zhao C; Amin M; Weng B; Chen X; Kanbour-Shakir A; Austin RM
Arch Pathol Lab Med; 2013 Jul; 137(7):942-7. PubMed ID: 23050808
[TBL] [Abstract][Full Text] [Related]
14. HPV Cotesting of Unsatisfactory Papanicolaou Tests: Implications for Follow-up Intervals.
Chen F; Hsu Lin L; Hindi I; Sun W; Shafizadeh N; Szeto O; Brandler TC; Simsir A
Am J Clin Pathol; 2023 Aug; 160(2):137-143. PubMed ID: 37052613
[TBL] [Abstract][Full Text] [Related]
15. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
16. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
[TBL] [Abstract][Full Text] [Related]
17. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
18. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
19. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
20. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
Wong AK; Chan RC; Nichols WS; Bose S
Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
